This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2003 Jun;16(6):512-4.

doi: 10.1016/s0895-7061(03)00856-2.

ALLHAT and beyond

Michael H Alderman

PMID: 12799104
DOI: 10.1016/s0895-7061(03)00856-2

Editorial

ALLHAT and beyond

Michael H Alderman. Am J Hypertens. 2003 Jun.

. 2003 Jun;16(6):512-4.

doi: 10.1016/s0895-7061(03)00856-2.

Author

Michael H Alderman

PMID: 12799104
DOI: 10.1016/s0895-7061(03)00856-2

No abstract available

PubMed Disclaimer

Comment on

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA. 2002 Dec 18;288(23):2981-97. doi: 10.1001/jama.288.23.2981. JAMA. 2002. PMID: 12479763 Clinical Trial.

Similar articles

Comments on the renal aspects of the ALLHAT study.
Ruilope LM. Ruilope LM. J Hypertens. 2003 Feb;21(2):235-6. doi: 10.1097/00004872-200302000-00005. J Hypertens. 2003. PMID: 12569244 Review. No abstract available.
The ALLHAT trial: strengths and limitations.
Fagard RH. Fagard RH. J Hypertens. 2003 Feb;21(2):229-32. doi: 10.1097/00004872-200302000-00003. J Hypertens. 2003. PMID: 12569242 Review. No abstract available.
The ALLHAT trial: a verdict or a challenge?
Zanchetti A, Mancia G. Zanchetti A, et al. J Hypertens. 2003 Feb;21(2):223. doi: 10.1097/00004872-200302000-00001. J Hypertens. 2003. PMID: 12569240 No abstract available.
ALLHAT and ANBP2: what have we learned from recent mega-trials?
Sander GE, Giles TD. Sander GE, et al. Am J Geriatr Cardiol. 2003 Jul-Aug;12(4):267-71. doi: 10.1111/j.1076-7460.2003.02468.x. Am J Geriatr Cardiol. 2003. PMID: 12888711 Review. No abstract available.
All hats off to ALLHAT: a massive study with clear messages.
Chalmers J. Chalmers J. J Hypertens. 2003 Feb;21(2):225-8. doi: 10.1097/00004872-200302000-00002. J Hypertens. 2003. PMID: 12569241 Review. No abstract available.

See all similar articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems
Medical
- MedlinePlus Health Information